South Korea approves Phase 2/3 trials of Celltrion's COVID-19 antibody drug
South Korea said on Thursday it has approved Celltrion Inc's
experimental COVID-19 treatment for Phase 2/3 clinical trials, as
the ... |
Updates & Legacy — Stigmabase is a Canadian Non-Governmental & Nonprofit Initiative. Our mission is to inform about stigma around the world and make the data collected accessible for researchers. Stigmabase is very attentive to misinformation and lists only reliable sources. — The marginalization of individuals or categories of individuals is a too common phenomenon. Millions of people are facing this problem around the world and many complex factors are involved.